Clinical Trial Update: Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR [Phase 3]

View source ↗

Summary

A Phase III trial comparing Tarceva (erlotinib) to standard chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR TK-domain mutations…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Spanish Lung Cancer Group | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2025-03-05